Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of cytisine in medicines for treating cerebral arterial thrombosis

A technology for ischemic cerebral apoplexy and indigoline, which is applied in drug combinations, medical preparations containing active ingredients, blood diseases, etc., to achieve the effects of reducing brain tissue damage, inhibiting expression, and improving neurological dysfunction.

Inactive Publication Date: 2015-04-01
NINGXIA MEDICAL UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In 2013, it was reported in China that cydidine has a certain neuroprotective effect on glutamate excitotoxicity injury of neuron cells cultured in vitro, but whether it has neuroprotective effect on excitotoxic amino acid injury caused by cerebral ischemia in vivo and the possible The mechanism has not been reported at home and abroad. Therefore, it has extremely high potential value and social significance to develop it into a drug for the treatment of ischemic stroke.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cytisine in medicines for treating cerebral arterial thrombosis
  • Application of cytisine in medicines for treating cerebral arterial thrombosis
  • Application of cytisine in medicines for treating cerebral arterial thrombosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Cynicine is used as a drug for the treatment of ischemic stroke, and the structural formula of Cynicine is as shown in formula (1):

[0045]

[0046] Among them, ischemic stroke is ischemic stroke in the acute phase, and the single application dose of cydinidine is limited to the dose that does not cause blood sugar drop. Injectable form.

Embodiment 2

[0048] Cynicine is used as a drug for the treatment of ischemic stroke, and the structural formula of Cynicine is as shown in formula (1):

[0049]

[0050] Among them, the ischemic stroke is ischemic stroke in the repair period, the single application dose of cydidine is limited to the dose that does not cause blood sugar drop, the single application dose of cydidine is 0.5mg / kg for mice, and the dosage form of the drug is Injection powder form.

Embodiment 3

[0052] Cynicine is used as a drug for the treatment of ischemic stroke, and the structural formula of Cynicine is as shown in formula (1):

[0053]

[0054] Among them, the ischemic stroke is ischemic stroke in the repair period, the single application dose of cydidine is limited to the dose that does not cause blood sugar drop, the single application dose of cydidine is 1mg / kg for mice, and the dosage form of the drug is injection powder form.

[0055] The following animal experiment has further illustrated the effect of above-mentioned embodiment 1 to 3:

[0056] 1. Experimental materials

[0057] 1.1 Animal handling

[0058] 2-3 months old, male ICR mice, 25-30 g, purchased from the Experimental Animal Center of Ningxia Medical University, animal production license number: NCXK (Ning) 2013-0005. Feeding conditions include standard feed, tap water, room temperature maintained at (24±2)°C, humidity 50-60%, and daily light and dark times of 12 hours each. Before the exp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of cytisine (CYT) in medicines for treating cerebral arterial thrombosis. Experiment results indicate that when the cytisine is 1mg / kg which is in a safety dosage range, the autonomic dysfunction of a mouse focal cerebral ischemia model can be remarkably improved, the volume of cerebral infarction in an ischemia area and the apoptosis rate in an ischemic core area and penumbra can be reduced, and a certain dose-pharmacological effect correlation is represented. The experiment results prove that the cytisine has the effects of preventing occurrence of local cerebral arterial thrombosis, reducing death and disability after stroke and promoting neurological function recovery.

Description

technical field [0001] The invention relates to the application of cynicine, in particular to the application of cynicine as a drug for treating ischemic stroke. Background technique [0002] Stroke (stroke) is a disease with acute onset and rapid progression, characterized by insufficiency of cerebral blood supply and circulatory disturbance, characterized by autonomic impairment and loss of cognitive function. The etiology is mainly that the stenosis or occlusion of the cerebral artery lumen causes ischemic damage to the brain tissue in the area dominated by the artery, and the systemic circulation disorder (such as hypotension, cardiac arrest, ischemic shock) leads to transient ischemic attack. Clinically, it manifests as symptoms and signs of transient or irreversible neurological dysfunction, and has the characteristics of high morbidity, high mortality, high disability, high recurrence rate, etc., and most of the surviving patients have hemiplegia, aphasia, etc. disfu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/439A61P9/10A61P7/10A61P25/00
CPCA61K31/439
Inventor 余建强王永胜周茹李玉香郑婕吴璟乔海琦刘河涛
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com